A Phase 2 interventional study of Voclosporin and tacrolimus in Kidney Diseases, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 45 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-02-12.
Sponsored by Aurinia Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing tacrolimus in Kidney Diseases — none open to participants now, 1 under way, 1 of them phase 3. Tacrolimus · Kidney Diseases.
Among the 13 studies testing tacrolimus in Kidney Diseases, this one is the 2nd largest by enrollment, is one of 3 that started in 2006, is the only one in phase 2, and was the 3rd registered.
970 studies on the registry are indexed under Kidney Diseases; 184 are open to participants now.
Browse Kidney Diseases studies →None of the 13 studies testing tacrolimus in Kidney Diseases is open now. The open studies under Kidney Diseases, anywhere →
Tacrolimus: first FDA approval 1994 (PROGRAF), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 130 Kidney Diseases studies recruiting now, 76 (58%) set no upper age limit and 34 (26%) stop at 75 or younger; 26 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 5 · Phase 4 4
First in 2001; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 334 is above the median of 64 across 647 interventional studies indexed under Kidney Diseases.
Median enrollment 94 across the 13 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
Aurinia Pharmaceuticals Inc. is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Aurinia Pharmaceuticals Inc. has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing tacrolimus in Kidney Diseases, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will see if voclosporin is safe and effective in preventing kidney transplant rejection.
Prograf® (tacrolimus) is associated with numerous side effects, including neurotoxicity, nephrotoxicity, polyoma nephropathy, QT prolongation, and New Onset Diabetes Mellitus After Transplant (NODAT). Voclosporin is a novel calcineurin inhibitor intended for use in the prevention of organ graft rejection.
Comparison(s): Voclosporin at 3 dose levels (0.4, 0.6, and 0.8 mg/kg twice a day) compared to tacrolimus
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Low dose voclosporin
Drug: Voclosporin
Mid Dose Voclosporin
Drug: Voclosporin
High Dose Voclosporin
Drug: Voclosporin
Standard Dose Tacrolimus
Drug: tacrolimus
voclosporin 0.4, 0.6, 0.8 mg/kg po BID
Also known as: ISA247
tacrolimus 0.05 mg/kg po BID
Biopsy Proven Acute Rejection (BPAR)
The primary objective of the PROMISE trial was to demonstrate noninferiority of biopsy proven acute rejection (BPAR) rate in de novo renal transplant patients at 6 months in at least one VCS treatment group.
Time frame: Six months
To Demonstrate a 5% Improvement in Renal Function as Measured by Iothalamate Glomerular Filtration Rate (GFR)
ANOVAs to test for differences in GFR at Month 6.
Time frame: Six months
The Pharmacokinetic-pharmacodynamic Relationship Between Voclosporin and Calcineurin Inhibition (CNi), or Tacrolimus and Calcineurin Inhibition
A sparse sampling protocol of whole blood samples obtained on Day 180 at time points immediately prior to drug administration and at 1, 2, and 4 hours post-dose were utilized. Standard non-compartmental analysis (NCA) was performed on whole blood concentration data for voclosporin and its metabolites, tacrolimus, MPA (mycophenolic acid) and MPAG (mycophenolic acid glucuronide). Tmax and Cmax were obtained directly from the concentration-time profiles without interpolation. AUC(0-4)\[area under the curve\] was calculated using log-linear trapezoidal rule. Cmax, AUC(0-4), C0 and C2 were summarized using descriptive statistics.
Time frame: Six months
Patient Survival
Time frame: Six months
Graft Survival
Time frame: Six months
Hypertension, Hyperlipidemia, or Hyperglycemia
Time frame: Six months
A Composite of Biopsy-proven Chronic Rejection Graft Loss, Death, or Lost to Follow up.
Time frame: Six months
A total of 334 de novo renal transplant patients were recruited in 36 US and 4 Canadian transplant centres between January 2006 and December 2007.
| Milestone | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| Started | 87 | 77 | 84 | 86 |
| Completed | 70 | 64 | 62 | 81 |
| Not completed | 17 | 13 | 22 | 5 |
The primary objective of the PROMISE trial was to demonstrate noninferiority of biopsy proven acute rejection (BPAR) rate in de novo renal transplant patients at 6 months in at least one VCS treatment group.
| percentage of participants | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| Biopsy Proven Acute Rejection (BPAR) | 2.3 (— to 1.3) | 9.1 (— to 10.8) | 10.7 (— to 11.4) | 5.8 (0 to 0) |
ANOVAs to test for differences in GFR at Month 6.
| mL/min | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| To Demonstrate a 5% Improvement in Renal Function as Measured by Iothalamate Glomerular Filtration Rate (GFR) | 68 ± 13 | 72 ± 12 | 71 ± 13 | 69 ± 29 |
A sparse sampling protocol of whole blood samples obtained on Day 180 at time points immediately prior to drug administration and at 1, 2, and 4 hours post-dose were utilized. Standard non-compartmental analysis (NCA) was performed on whole blood concentration data for voclosporin and its metabolites, tacrolimus, MPA (mycophenolic acid) and MPAG (mycophenolic acid glucuronide). Tmax and Cmax were obtained directly from the concentration-time profiles without interpolation. AUC(0-4)\[area under the curve\] was calculated using log-linear trapezoidal rule. Cmax, AUC(0-4), C0 and C2 were summarized using descriptive statistics.
| % Calcineurin (CNi) compared to baseline | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| The Pharmacokinetic-pharmacodynamic Relationship Between Voclosporin and Calcineurin Inhibition (CNi), or Tacrolimus and Calcineurin Inhibition | 57.3 ± 14.4 | 47.5 ± 16.4 | 38.8 ± 16.3 | 23.0 ± 13.8 |
| Percentage of patients | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| Patient Survival | 98.9 | 100 | 100 | 97.7 |
| Percentage of patients | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| Graft Survival | 98.9 | 100 | 100 | 97.7 |
| Percentage of patients | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| Treatment with an Antihypertensive | 96.6 ± 1 | 97.4 ± 1 | 96.4 ± 1.2 | 95.3 ± 1.2 |
| Triglyceride values > ULN | 28 ± 18 | 30 ± 18 | 18 ± 22 | 39 ± 16 |
| New Onset of Diabetes Mellitus After Transplant | 17.7 | 5.7 | 1.6 | 16.4 |
| Percentage of patients | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| A Composite of Biopsy-proven Chronic Rejection Graft Loss, Death, or Lost to Follow up. | 5.6 | 7.4 | 3.7 | 3.9 |
Collected over 6 month treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| High Dose Voclosporin | — | 40/87 (46%) | 84/87 (96.6%) |
| Mid Dose Voclosporin | — | 35/77 (45.5%) | 76/77 (98.7%) |
| Low Dose Voclosporin | — | 36/84 (42.9%) | 83/84 (98.8%) |
| Tacrolimus | — | 37/86 (43%) | 85/86 (98.8%) |
| Event | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| Kidney Transplant RejectionImmune system disorders | 4/87 | 10/77 | 18/84 | 6/86 |
| Blood Creatinine IncreasedInvestigations | 6/87 | 3/77 | 3/84 | 3/86 |
| HydronephrosisRenal and urinary disorders | 0/87 | 4/77 | 0/84 | 2/86 |
| PyrexiaGeneral disorders | 1/87 | 3/77 | 0/84 | 3/86 |
| DehydrationMetabolism and nutrition disorders | 3/87 | 1/77 | 0/84 | 3/86 |
| Complications of Transplanted KidneyInjury, poisoning and procedural complications | 3/87 | 0/77 | 0/84 | 0/86 |
| Urinary Tract InfectionInfections and infestations | 1/87 | 2/77 | 0/84 | 1/86 |
| HypertensionVascular disorders | 0/87 | 0/77 | 2/84 | 0/86 |
| GastroenteritisInfections and infestations | 0/87 | 0/77 | 0/84 | 2/86 |
| International Normalised Ratio DecreasedInvestigations | 0/87 | 0/77 | 0/84 | 2/86 |
| Event | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus |
|---|---|---|---|---|
| CONSTIPATIONGastrointestinal disorders | 35/87 | 34/77 | 43/84 | 31/86 |
| DIARRHOEAGastrointestinal disorders | 31/87 | 29/77 | 16/84 | 43/86 |
| HYPOMAGNESAEMIAMetabolism and nutrition disorders | 34/87 | 21/77 | 22/84 | 37/86 |
| NAUSEAGastrointestinal disorders | 36/87 | 28/77 | 36/84 | 35/86 |
| HYPOPHOSPHATAEMIAMetabolism and nutrition disorders | 28/87 | 32/77 | 32/84 | 34/86 |
| OEDEMA PERIPHERALGeneral disorders | 28/87 | 31/77 | 24/84 | 23/86 |
| INSOMNIAPsychiatric disorders | 20/87 | 20/77 | 19/84 | 33/86 |
| PROCEDURAL PAINInjury, poisoning and procedural complications | 29/87 | 28/77 | 28/84 | 30/86 |
| ANAEMIABlood and lymphatic system disorders | 27/87 | 24/77 | 30/84 | 27/86 |
| HYPERTENSIONVascular disorders | 23/87 | 23/77 | 29/84 | 26/86 |
| Age, Categorical(Participants) | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 82 | 76 | 79 | 82 | 319 |
| >=65 years | 5 | 1 | 5 | 4 | 15 |
| Sex: Female, Male(Participants) | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus | Total |
|---|---|---|---|---|---|
| Female | 24 | 25 | 33 | 31 | 113 |
| Male | 63 | 52 | 51 | 55 | 221 |
| Region of Enrollment(participants) | High Dose Voclosporin | Mid Dose Voclosporin | Low Dose Voclosporin | Tacrolimus | Total |
|---|---|---|---|---|---|
| United States | 74 | 67 | 74 | 75 | 290 |
| Canada | 13 | 10 | 10 | 11 | 44 |
The record gives a start of Jan 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 3 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Voclosporin · Tacrolimus
Aurinia Pharmaceuticals Inc.